BR112014031234A2 - derivados de piridinona e piridazinona - Google Patents

derivados de piridinona e piridazinona

Info

Publication number
BR112014031234A2
BR112014031234A2 BR112014031234A BR112014031234A BR112014031234A2 BR 112014031234 A2 BR112014031234 A2 BR 112014031234A2 BR 112014031234 A BR112014031234 A BR 112014031234A BR 112014031234 A BR112014031234 A BR 112014031234A BR 112014031234 A2 BR112014031234 A2 BR 112014031234A2
Authority
BR
Brazil
Prior art keywords
pyridinone
pyridazinone derivatives
compounds
formula
diseases
Prior art date
Application number
BR112014031234A
Other languages
English (en)
Inventor
H Park Chang
Sun Chaohong
Liu Dachun
S Sheppard George
H Holms James
K Pratt John
F Mcdaniel Keiyh
Wang Le
D Wendt Michael
D Hubbard Robert
N Soltwedel Todd
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112014031234A2 publication Critical patent/BR112014031234A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

resumo “derivados de piridinona e piridazinona” a presente invenção fornece os compostos da fórmula (i) (i) em que a1, a2, a3, a4, j e x3 têm qualquer um entre os valores definidos no relatório descritivo, e sais farmaceuticamente aceitáveis dos mesmos, os quais são úteis como agentes no tratamento de doenças e condições, incluindo doenças infla-matórias, diabetes, obesidade, câncer e aids. composições farmacêuticas compre-endendo um ou mais compostos da fórmula i também são fornecidas.
BR112014031234A 2012-06-12 2013-06-11 derivados de piridinona e piridazinona BR112014031234A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/076748 WO2013185284A1 (en) 2012-06-12 2012-06-12 Pyridinone and pyridazinone derivatives
US13/796,437 US9561231B2 (en) 2012-06-12 2013-03-12 Pyridinone and pyridazinone derivatives
PCT/US2013/045151 WO2013188381A1 (en) 2012-06-12 2013-06-11 Pyridinone and pyridazinone derivatives

Publications (1)

Publication Number Publication Date
BR112014031234A2 true BR112014031234A2 (pt) 2017-06-27

Family

ID=49715789

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014031068A BR112014031068A2 (pt) 2012-06-12 2012-06-12 derivados piridinona e piridazinona
BR112014031234A BR112014031234A2 (pt) 2012-06-12 2013-06-11 derivados de piridinona e piridazinona

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112014031068A BR112014031068A2 (pt) 2012-06-12 2012-06-12 derivados piridinona e piridazinona

Country Status (15)

Country Link
US (1) US9561231B2 (pt)
EP (2) EP2858982A4 (pt)
JP (2) JP6215315B2 (pt)
KR (2) KR20150023722A (pt)
CN (2) CN104718201A (pt)
AU (4) AU2012382373A1 (pt)
BR (2) BR112014031068A2 (pt)
CA (2) CA2874953A1 (pt)
HK (2) HK1208681A1 (pt)
IL (2) IL236036A0 (pt)
MX (2) MX2014015156A (pt)
RU (2) RU2632915C2 (pt)
SG (2) SG11201408324QA (pt)
TW (1) TWI592398B (pt)
WO (2) WO2013185284A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CN104718201A (zh) * 2012-06-12 2015-06-17 艾伯维公司 吡啶酮和哒嗪酮衍生物
EP2958909A1 (de) 2013-02-19 2015-12-30 Bayer Pharma Aktiengesellschaft Bicyclo- und spirocyclisch substituierte 2,3-benzodiazepine
EP2958923A1 (de) 2013-02-22 2015-12-30 Bayer Pharma Aktiengesellschaft 4-substituierte pyrrolo- und pyrazolo-diazepine
US20160009725A1 (en) 2013-02-22 2016-01-14 Bayer Pharma Aktiengesellschaft Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases
AU2014249192B2 (en) 2013-03-11 2017-12-21 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
BR112015022942B1 (pt) 2013-03-15 2022-02-22 Incyte Holdings Corporation Compostos heterocíciclos tricíclicos, método para inibir proteína bet in vitro e composição farmacêutica compreendendo os referidos compostos
JP2016523964A (ja) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
PL3640241T3 (pl) * 2013-10-18 2022-12-05 Celgene Quanticel Research, Inc. Inhibitory bromodomeny
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
JP2016539970A (ja) * 2013-12-09 2016-12-22 アッヴィ・インコーポレイテッド ブロモドメイン阻害薬として有用なジヒドロピリジノンおよびジヒドロピリダジノン誘導体
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
CN107074861A (zh) 2014-02-28 2017-08-18 密执安大学评议会 作为bet溴结构域抑制剂的9h嘧啶并[4，5‑b]吲哚和相关类似物
NZ763740A (en) 2014-04-23 2023-06-30 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
KR102438302B1 (ko) * 2014-06-27 2022-08-30 셀젠 콴티셀 리서치, 인크. 리신 특이적 데메틸라제-1의 억제제
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
US10307407B2 (en) 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
PL3319959T3 (pl) 2015-07-06 2022-02-14 Alkermes, Inc. Hetero-haloinhibitory deacetylazy histonowej
GB201514015D0 (en) 2015-08-07 2015-09-23 Arnér Elias S J And Dept Of Health And Human Services Novel pyridazinones and their use in the treatment of cancer
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
WO2017024408A1 (en) 2015-08-11 2017-02-16 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
WO2017024412A1 (en) 2015-08-12 2017-02-16 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
UY36875A (es) 2015-09-02 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
WO2017066876A1 (en) * 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
AU2016346303B2 (en) 2015-10-28 2021-01-07 Fmc Corporation Novel pyrdazinone herbicides
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
WO2017127930A1 (en) * 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
US11548899B2 (en) 2016-02-15 2023-01-10 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
CA3020281A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
US11192898B2 (en) 2016-04-06 2021-12-07 The Regents Of The University Of Michigan MDM2 protein degraders
AU2017250076B2 (en) 2016-04-12 2021-07-22 The Regents Of The University Of Michigan Bet protein degraders
PL3442972T3 (pl) 2016-04-15 2020-07-27 Abbvie Inc. Inhibitory bromodomeny
FI3472157T3 (fi) 2016-06-20 2023-06-01 Incyte Corp Bet-inhibiittorin kiteisiä kiinteitä muotoja
JP6961684B2 (ja) 2016-09-13 2021-11-05 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔタンパク質分解物質としての縮合１，４−オキサゼピン
ES2857743T3 (es) 2016-09-13 2021-09-29 Univ Michigan Regents 1,4-diazepinas fusionadas como degradadores de proteína BET
EP3825313A1 (en) * 2016-10-14 2021-05-26 AbbVie Inc. Pyridin-2(1h)-one derivatives as bromodomain inhibitors
EP3800182A1 (en) * 2016-10-14 2021-04-07 AbbVie Inc. Pyridin-2(1h)-one derivatives as bromodomain inhibitors
WO2018086605A1 (zh) 2016-11-10 2018-05-17 山东罗欣药业集团股份有限公司 一种含氮大环类化合物、其制备方法、药物组合物及应用
WO2018132533A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
WO2018144789A1 (en) 2017-02-03 2018-08-09 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
JP2020516672A (ja) * 2017-04-18 2020-06-11 セルジーン クオンティセル リサーチ，インク． 治療用化合物
SI3664802T1 (sl) 2017-08-07 2022-10-28 Alkermes, Inc. Biciklični zaviralci histon deacetilaze
CA3073543A1 (en) * 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. Benzosulfonyl compounds
ES2910839T3 (es) * 2017-08-23 2022-05-13 Sprint Bioscience Ab Compuestos de piridilpiridona
WO2019055444A1 (en) 2017-09-13 2019-03-21 The Regents Of The University Of Michigan DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
KR102026243B1 (ko) * 2018-01-19 2019-09-27 연세대학교 산학협력단 백혈병 치료용 약학적 조성물
CN111646979B (zh) * 2018-01-23 2021-08-31 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
WO2019222431A1 (en) 2018-05-16 2019-11-21 Vivace Therapeutics, Inc. Oxadiazole compounds
CN108929275B (zh) * 2018-06-14 2021-08-24 沈阳药科大学 6-(3,4-取代苯基)-3-氧代-2,3-二氢哒嗪-4-酰肼类化合物及其用途
KR20210069652A (ko) * 2018-09-18 2021-06-11 골드핀치 바이오 인코포레이티드 피리다지논 및 이의 사용 방법
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN117083064A (zh) 2020-11-25 2023-11-17 德西费拉制药有限责任公司 作为vps34抑制剂用于治疗病毒感染的吡啶基吡啶酮衍生物
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023146512A1 (en) * 2022-01-25 2023-08-03 Vivace Therapeutics, Inc. Compounds and methods of use thereof
WO2023215559A1 (en) * 2022-05-05 2023-11-09 Aria Pharmaceuticals, Inc. Compounds, compositions, and methods
CN116003315A (zh) * 2023-01-09 2023-04-25 中国药科大学 一种双芳基醚吡啶酮类化合物及其制备方法与应用

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445510A1 (de) 1963-11-08 1969-03-13 Basf Ag Verfahren zur Herstellung von 4-Nitro-5-chlor- bzw. -brompyridazonen
DE2845456A1 (de) 1978-10-19 1980-08-14 Merck Patent Gmbh 6-arylpyridazin-3-one und verfahren zu ihrer herstellung
JPS5795964A (en) 1980-12-04 1982-06-15 Morishita Seiyaku Kk Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4404203A (en) 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
ZA834032B (en) * 1982-06-05 1984-04-25 Smith Kline French Lab Heterocyclic compounds
US4657906A (en) 1982-06-05 1987-04-14 Smith Kline & French Laboratories Ltd. Heterocyclic compounds having inotropic activity
EP0096517A3 (en) * 1982-06-05 1985-04-03 Smith Kline & French Laboratories Limited Aryl pyrazinones
US4734415A (en) 1982-08-13 1988-03-29 Warner-Lambert Company Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
DE3433953A1 (de) * 1984-09-15 1986-03-27 A. Nattermann & Cie GmbH, 5000 Köln Neue, eine imidazol-gruppe enthaltende 3,4-dihydro-2(1h)-pyridone und2(1h)-pyridone, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
ES2075071T3 (es) 1988-10-20 1995-10-01 Sandoz Ag Colorantes azoicos reactivos con fibras.
DE4023369A1 (de) 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH0578250A (ja) 1991-09-18 1993-03-30 Fujisawa Pharmaceut Co Ltd 肝炎または膵炎の予防・治療剤
JPH05148222A (ja) 1991-11-29 1993-06-15 Fujirebio Inc ナフトエ酸誘導体
US5664029A (en) 1992-05-13 1997-09-02 Apple Computer, Inc. Method of disregarding changes in data in a location of a data structure based upon changes in data in nearby locations
DE4237656A1 (de) 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
US5574030A (en) 1992-07-14 1996-11-12 Nippon Chemiphar Co., Ltd. N-aminoalkyl-substituted nitrogen-containing five membered heterocyclic compounds
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
AU5891494A (en) 1993-01-29 1994-08-15 Nippon Soda Co., Ltd. Heterocyclic derivative
US5852006A (en) 1993-04-30 1998-12-22 Nippon Chemiphar Co., Ltd. N-aminoalkyl-substituted nitrogen-containing six membered heterocyclic compounds
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
WO1996010559A1 (en) 1994-10-04 1996-04-11 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
IL115889A0 (en) 1994-11-14 1996-01-31 Rohm & Haas Pyridazinones and their use as fungicides
WO1996033994A1 (fr) 1995-04-28 1996-10-31 Nippon Soda Co., Ltd. Derives amino-substitues, leur procede de preparation et herbicide
AR003978A1 (es) 1995-08-25 1998-09-30 Rohm & Haas Composiciones de acidos grasos y piridazinonas que tienen efectos fungitoxicos sinergicos y metodos para controlar hongos.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
WO1997020822A1 (en) 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
WO1998011111A1 (fr) 1996-09-13 1998-03-19 Yoshitomi Pharmaceutical Industries, Ltd. Composes de thienotriazolodiazepine et leurs utilisations a des fins medicinales
US5855654A (en) 1997-01-30 1999-01-05 Rohm And Haas Company Pyridazinones as marine antifouling agents
WO1998043971A1 (en) 1997-04-01 1998-10-08 Astra Pharmaceuticals Ltd. Novel pyridine derivatives and pharmaceutical compositions containing them
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
JPH1149755A (ja) 1997-07-30 1999-02-23 Nippon Kayaku Co Ltd 新規含窒素ヘテロ環誘導体およびそれを有効成分とする殺虫殺ダニ組成物
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
EP1086948A4 (en) 1998-02-25 2004-03-10 Sumitomo Pharma PYRIDONE DERIVATIVES AND THEIR MANUFACTURING PROCESS
JP2000178258A (ja) 1998-10-09 2000-06-27 Nippon Nohyaku Co Ltd フェニルピリダジノン誘導体
JP2000170870A (ja) 1998-12-04 2000-06-23 Toyota Autom Loom Works Ltd 動力伝達機構
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6063781A (en) 1999-02-17 2000-05-16 Lai; Hoi Kiong Pesticidal phenylpyridazinone derivatives
DE19918294A1 (de) 1999-04-22 2000-10-26 Bayer Ag O-Aryldithiazoldioxide
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
CN1297916A (zh) 1999-11-26 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人含溴基结构域的蛋白95和编码这种多肽的多核苷酸
DE10010429A1 (de) 2000-03-03 2001-09-06 Bayer Ag Neue 6-[4-Sulfonamidophenyl]-dihydropyridazinone und ihre Verwendung
CN1315397A (zh) 2000-03-28 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人溴基结构域10和编码这种多肽的多核苷酸
HUP0700086A2 (en) * 2000-08-11 2007-05-29 Eisai Co Ltd 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them
WO2002072103A1 (en) 2001-02-12 2002-09-19 Merck Patent Gmbh Use of type 4 phosphodiesterase inhibitors in myocardial diseases
JP2005515975A (ja) 2001-10-31 2005-06-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４型ホスホジエステラーゼ阻害剤およびこれらの使用
TW200406466A (en) 2001-11-13 2004-05-01 Ciba Sc Holding Ag Compositions comprising at least one oxonol dye and at least one metal complex
US20050043315A1 (en) 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
JP2003313169A (ja) 2002-04-19 2003-11-06 Otsuka Chemical Holdings Co Ltd ４，４−ジフルオロ−３−ブテニル化合物及び農園芸用殺虫・殺ダニ剤
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
US20040067955A1 (en) * 2002-09-06 2004-04-08 Fujisawa Pharmaceutical Co. Ltd. Pyridazinone compound and pharmaceutical use thereof
AU2003274025A1 (en) 2002-10-17 2004-05-04 Syngenta Participations Ag Pyridine derivatives useful as herbicides
MXPA05011539A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
BRPI0415390A (pt) 2003-10-14 2006-12-12 Pharmacia Corp compostos de pirazinona substituìda para o tratamento da inflamação
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
SE0400014D0 (sv) 2004-01-08 2004-01-08 Astrazeneca Ab Heterocyclic derivatives
JP2005255675A (ja) 2004-02-09 2005-09-22 Tanabe Seiyaku Co Ltd 医薬組成物
BRPI0509467A (pt) 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
US7223733B2 (en) 2004-03-31 2007-05-29 National University Of Singapore Modulation of TRIP-Br function and method of treating proliferative disorders
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
US7087622B2 (en) 2004-05-07 2006-08-08 Janssen Pharmaceutica N.V. Pyridone compounds as inhibitors of bacterial type III protein secreation systems
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
WO2006060127A2 (en) 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
JP2008545622A (ja) 2005-05-03 2008-12-18 ダウ アグロサイエンシィズ エルエルシー 置換４，５−ジヒドロ−１，２，４−トリアジン−６−オン類、１，２，４−トリアジン−６−オン類およびそれらの殺真菌剤としての用途
JP5159305B2 (ja) 2005-05-30 2013-03-06 田辺三菱製薬株式会社 チエノトリアゾロジアゼピン化合物及びその医薬としての用途
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
WO2007008144A1 (en) 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
EP2004632B1 (en) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2008012622A2 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
MX2009000884A (es) 2006-07-25 2009-06-05 Cephalon Inc Derivados de piridizinona.
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
PE20080839A1 (es) * 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
CN101636386A (zh) 2006-12-14 2010-01-27 安斯泰来制药有限公司 用作crth2拮抗剂和抗过敏剂的多环酸化合物
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
KR101335845B1 (ko) 2007-02-15 2013-12-02 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
DE102007025718A1 (de) 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
DE102007025717A1 (de) 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
GB0719751D0 (en) 2007-10-10 2007-11-21 Antoxis Ltd In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells
US8188080B2 (en) 2007-10-17 2012-05-29 Sanford-Burnham Medical Research Institute VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
WO2009084693A1 (ja) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
WO2009102428A2 (en) 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
US20110105504A1 (en) 2008-03-18 2011-05-05 Vitae Pharmaceuticals ,Inc. Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1
AU2009233862B2 (en) 2008-04-08 2014-10-30 Dow Agrosciences Llc 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and their use as fungicides
BRPI0914772A2 (pt) 2008-06-25 2015-10-20 Envivo Pharmaceuticals Inc compostos heterocíclicos 1,2-dissubstituídos
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
WO2010029299A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Pyrimidinone derivaties for use as medicaments
CN102245574A (zh) * 2008-12-08 2011-11-16 欧洲筛选有限公司 用于治疗代谢疾病的化合物、药物组合物以及方法
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
PL2617420T3 (pl) 2009-05-07 2016-04-29 Forum Pharmaceuticals Inc Heterocykliczne związki fenoksymetylu
JP5524343B2 (ja) 2009-11-05 2014-06-18 グラクソスミスクライン エルエルシー ベンゾジアゼピンブロモドメイン阻害剤
EP2955524A3 (en) 2009-11-05 2016-03-23 GlaxoSmithKline LLC Novel process
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ME02356B (me) 2009-11-05 2016-06-20 Glaxosmithkline Llc Inhibitor bromodomena benzodiazepina
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CA2789474A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
EP2569286B1 (en) * 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2012075456A1 (en) * 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012129013A1 (en) 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
CN104024259B (zh) * 2011-09-27 2017-09-26 基恩菲特公司 作为Rev‑Erb激动剂的6‑取代的***并哒嗪类衍生物
CN104718201A (zh) * 2012-06-12 2015-06-17 艾伯维公司 吡啶酮和哒嗪酮衍生物

Also Published As

Publication number Publication date
US20130331382A1 (en) 2013-12-12
WO2013188381A1 (en) 2013-12-19
AU2017268560A1 (en) 2017-12-21
SG11201408186TA (en) 2015-01-29
BR112014031068A2 (pt) 2017-06-27
EP2858990B8 (en) 2018-07-04
EP2858990A1 (en) 2015-04-15
US9561231B2 (en) 2017-02-07
CA2875016A1 (en) 2013-12-19
TW201410651A (zh) 2014-03-16
CA2874953A1 (en) 2013-12-19
IL236037A0 (en) 2015-02-01
JP2015523347A (ja) 2015-08-13
TWI592398B (zh) 2017-07-21
EP2858982A4 (en) 2015-11-11
WO2013185284A1 (en) 2013-12-19
AU2018200802A1 (en) 2018-02-22
SG11201408324QA (en) 2015-01-29
HK1209109A1 (en) 2016-03-24
IL236036A0 (en) 2015-02-01
CN104718201A (zh) 2015-06-17
MX2014015158A (es) 2015-09-08
KR20150023722A (ko) 2015-03-05
CN104884451A (zh) 2015-09-02
AU2012382373A1 (en) 2014-12-11
RU2014153628A (ru) 2016-07-27
RU2632915C2 (ru) 2017-10-11
JP6224095B2 (ja) 2017-11-01
AU2013274465A1 (en) 2014-12-18
EP2858982A1 (en) 2015-04-15
EP2858990B1 (en) 2018-05-16
JP6215315B2 (ja) 2017-10-18
MX2014015156A (es) 2015-08-06
RU2014153626A (ru) 2016-07-27
HK1208681A1 (en) 2016-03-11
JP2015523354A (ja) 2015-08-13
KR20150023723A (ko) 2015-03-05

Similar Documents

Publication Publication Date Title
BR112014031234A2 (pt) derivados de piridinona e piridazinona
BR112015032710A2 (pt) inibidores de bromodomínio
BR112015022391A2 (pt) inibidores de domínio bromo tetracíclico
BR112015022551A2 (pt) inibidores de amido pirrol
BR112015022674A2 (pt) inibidores de bromodomínio
UY39630A (es) Inhibidores de bromodominios
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1124117T1 (el) Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
MX2014012695A (es) Derivados de isoindolona.
BR112015022861A2 (pt) inibidores de bromodomínio
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX2016007346A (es) Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
EA201391106A1 (ru) Новые гетероциклические производные
MX369417B (es) Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades.
BR112015021524A2 (pt) derivados de sulfonil quinolina e usos dos mesmos
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
MX2012008328A (es) Derivados de pirazina.
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.